# A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia

> **NCT00441116** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 153 (actual)

## Conditions studied

- Alopecia

## Interventions

- **DRUG:** Dutasteride 0.5mg oral tablets

## Key facts

- **NCT ID:** NCT00441116
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-15
- **Primary completion:** 2008-01-21
- **Final completion:** 2008-01-21
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441116, "A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00441116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*